TechBio x AI药物发现

Developing new drugsfaster and cheaper December 2025 Globally active European venture capital firm with a dedicatedHealth & Bio investment team. Global startup & venture capital intelligence platform. Dealroom.co is the foremost data provider on startup, early-stage andgrowth company ecosystems in Europe and around the globe. With more than €1.2 billion in AuM and six offices across EMEA, oursector-focusedinvestment teams back founders from pre–Seed toGrowth with long-term conviction, providing day-one access to our globalnetwork of corporate customers, experts, industry leaders, and top-tier Founded in Amsterdam in 2013, we now work with many of the world'smost prominent investors, entrepreneurs and government organizationsto provide transparency. Dealroom.co is a global intelligence platform fordiscovering and tracking the most promising companies, technologies The next decade will be transformational for health & bio, with Europe atthe forefront. Computing, AI, and biology are advancing at breakneckspeed, propelling a new wave of category-defining healthcare and life Dealroom partners closely with local tech ecosystem developmentagencies and enablers, to create a comprehensive multi-dimensionalblueprint of the tech ecosystem, including capital, talent, innovation, 1Introduction 2VC trends3Deep dive: Clinical Trial Tech4Deep dive: Chemical Synthesis5Spinouts & European initiatives In 2025, TechBio is moving from concept to reality After years of proving thatdata, computation, and biology canaccelerate discovery, TechBio companies arenow scaling. The era of theory is giving way to execution: platforms deliverpipelines, automation drivesreproducibility, and partnershipstransition frompilots to multi-step agreements. AI-discovereddrug candidatesare no longer confined to research, they are 31Number of AI-discoveredassets in clinical phase in » 150 TechBio companieslaunched in 2025 only 30%Share of drugsdiscovered via AI for all 30+Pharma contracts signedwith TechBio companies in In 2025, thereremains a negativerelationship between There is a clear mismatch betweenwhere VC money goes and where the realcosts sit in drug development. Targetdiscovery & validation attracts $1.8B infunding but represents only 3% of total This imbalance highlights a structuralinefficiency and a strong opportunity fortechnologies that can reduce risk, time, 670+ techbio x AI drug discovery startups in Europe 1Introduction 2VC trends 3Deep dive: Clinical Trial Tech4Deep dive: Chemical Synthesis 5Spinouts & European initiatives 2025 is already the 3rd best year to date with over $2B raised to date, driven byIsomorphic Labsʼ $600M round. Most of the top rounds are drug discovery tools. VC funding in European techbio & AI drug discovery startups» view online ▊$0–1m (pre-seed)▊$1–4m (seed)▊$4–15m (series A)▊$15–40m (series B)▊$40–100m (series C)▊$100–250m (mega rounds)▊$250m+ (mega+)▊Projection Early-stage VC funding in 2025 has already matched last yearʼs total, but across fewerrounds, driven by a rise in breakout funding, signaling growing market maturity Number of Early-stage and Breakout VC rounds in Europeantechbio & AI drug discovery startups ▊$0–1m (pre-seed)▊$1–4m (seed)▊$4–15m (series A)▊$15–40m (series B)▊$40–100m (series C)▊Projection The majorityof funding hashistorically beenallocated to Drug VC funding into European techbio & AIdrug discovery startups has grownstrongly, rising from ~$391M in 2015 to aprojected $2.1B in 2025. After a pullback in2023, funding is back up. Most capitalconcentrate in core discovery tools but Overall, this reflects both increasingmaturity of the ecosystem and a clearerbreakout between infrastructure plays and Fewer rounds, Largerchecks. Signs ofsector maturation Number of rounds into European techbio& AI drug discovery startups fell sharply in2023 and have since stabilised at a lower,projected ~118 rounds in 2025. At thesame time, total capital raised in 2025 has Overall, this signals a maturing sector, withcapital consolidating around scaledplatforms rather than broad-based New categories haveemerged such asCompliance, Virtual The fastest growth over the past decade has been in newly emerging categories.Compliance (+283%), virtual cell models(+187%) and biosecurity (+155%) haveexpanded rapidly, while more establishedareas like drug discovery tools (+69%) and The UK attracts more funding than the rest of Europe combined, driven byIsomorphicʼs $600M round, Spain and France follows Top European countries in techbio & AI drug discovery by VC funding in 2025and top funded companies of the year per country 2025 is on track to be the second strongest year in terms of exit activity. Since2021, exits have been mostly private, as public markets remain largely closed Big pharma is playing a catch-up on AI, as evidenced bytheir recent surge in investments in the field 1Introduction2VC trends 3Deep dive: Clinical Trial Tech 4Deep dive: Chemical Synthesis 5Spino